Drug recall · June 22, 2022
Zileuton Extended-Release Tablets recall
Why: Failed Dissolution Specifications: Out of specification test results observed in dissolution testing during long term stability study.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Zileuton Extended-Release Tablets, 600 mg, 120-count bottle, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD 21202 by Lupin Limited, Nagpur-441108, India, NDC 68180-169-16
- Lots / codes
Lots: M100070, M100239, Exp. 06/22, M100312, Exp.09/22, M100366, Exp.10/22
- Quantity
- 3,216 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Product was distributed to 10 wholesalers/distributors and one mail order account who may have further distributed the product nationwide.
- Initiated
- June 10, 2022 · Voluntary: Firm initiated
- Classified
- June 15, 2022
- Reported
- June 22, 2022
- Ended
- February 8, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Zileuton
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.